New Risk • Jun 26
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (0.09x net interest cover). Minor Risks Negative equity (-US$18m). Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (US$30.9m market cap). 공고 • May 09
Cryo-Cell International, Inc. Receives Acceptance of Compliance Plan from NYSE American On May 6, 2026, Cryo-Cell International, Inc. (the "Company") received a written notice from NYSE Regulation stating that it had accepted the Company's plan to regain compliance with the continued listing standards of the NYSE American LLC ("NYSE American"). As previously disclosed, the Company submitted a compliance plan to NYSE American on April 8, 2026. NYSE Regulation accepted the plan and granted the Company a plan period through September 9, 2027 to regain compliance with the applicable continued listing standards. During the plan period, the Company's common stock will continue to be listed and traded on NYSE American, subject to the Company's compliance with the initiatives and conditions set forth in the compliance plan and continued periodic review by NYSE Regulation. There can be no assurance that the Company will be able to regain compliance with the NYSE American continued listing standards by the September 9, 2027 plan period deadline. If the Company fails to regain compliance by such date, or fails to make progress consistent with the accepted compliance plan during the plan period, NYSE American may initiate delisting proceedings. Reported Earnings • Apr 16
First quarter 2026 earnings: EPS exceeds analyst expectations First quarter 2026 results: EPS: US$0.006 (down from US$0.035 in 1Q 2025). Revenue: US$7.68m (down 3.6% from 1Q 2025). Net income: US$47.1k (down 83% from 1Q 2025). Profit margin: 0.6% (down from 3.5% in 1Q 2025). Revenue was in line with analyst estimates. Earnings per share (EPS) exceeded analyst estimates. Revenue is expected to decline by 5.5% p.a. on average during the next 2 years, while revenues in the Healthcare industry in the US are expected to grow by 4.8%. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has remained flat, which means it is well ahead of earnings. 공고 • Mar 13
Cryo-Cell International, Inc. Receives NYSE American Continued Listing Notice Cryo-Cell International, Inc. announced that is has received a written notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance with certain continued listing standards set forth in the NYSE American Company Guide. Specifically, the Notice indicated that the Company is not in compliance with Section 1003 (a) of the NYSE American Company Guide because the Company reported (i) a stockholders’ deficit as of November 30, 2025, and (ii) net losses in two of its three most recent fiscal years ended November 30, 2023, November 30, 2024 and November 30, 2025. The Notice has no immediate effect on the listing or trading of the Company’s common stock, which will continue to trade on the NYSE American under the symbol “CCEL” while the Company pursues a plan to regain compliance. In accordance with NYSE American requirements, the Company intends to submit a plan to regain compliance within the prescribed timeframe. If the plan is accepted, the Company is typically granted a period of up to 18 months from receipt of the Notice to regain compliance. During this period, the Company’s common stock will continue to be listed and traded on the NYSE American, subject to the Company’s compliance with other listing requirements and the plan accepted by the NYSE American. There can be no assurance that the Company will be able to regain compliance within the allotted time or that the NYSE American will grant the Company an extension of time to regain compliance. If the Company fails to regain compliance or fails to maintain compliance with other listing requirements, the NYSE American may initiate delisting proceedings. Reported Earnings • Mar 02
Full year 2025 earnings: EPS misses analyst expectations Full year 2025 results: US$0.30 loss per share (down from US$0.049 profit in FY 2024). Revenue: US$31.6m (down 1.3% from FY 2024). Net loss: US$2.43m (down US$2.83m from profit in FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates. Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings. Buy Or Sell Opportunity • Dec 02
Now 25% undervalued after recent price drop Over the last 90 days, the stock has fallen 23% to US$3.57. The fair value is estimated to be US$4.76, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to decline by 4.6% in a year. Earnings are forecast to decline by 398% in the next year. 
